IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells

Cancer Letters

Volumn 354, Issue 2, 2014, Pages 254-262

  Singh, Ram K ^a   Gaikwad, Snehal M ^a   Jinager, Ankit ^a   Chaudhury, Smrita ^a   Maheshwari, Amita ^a   Ray, Pritha ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Chemoresistance; IGF 1R signaling; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PACLITAXEL; PICROPODOPHYLLIN; PROTEASOME; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; PODOPHYLLOTOXIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME DEGRADATION; FEMALE; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CANCER STAGING; DRUG RESISTANCE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PODOPHYLLOTOXIN; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTOR, IGF TYPE 1;

EID: 84907974000     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.08.023     Document Type: Article

References (39)

1. Ouban A., et al. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum. Pathol 2003, 34(8):803-808.
2. Baserga R., Peruzzi F., Reiss K. The IGF-1 receptor in cancer biology. Int. J. Cancer 2003, 107(6):873-877.
3. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129(7):1261-1274.
4. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298(5600):1911-1912.
5. Sell C., et al. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl Acad. Sci. U.S.A. 1993, 90(23):11217-11221.
6. Levine A.J., et al. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006, 20(3):267-275.
7. Scotlandi K., Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr. Opin. Oncol 2008, 20(4):419-427.
8. Beauchamp M.C., et al. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J. Oncol 2010, 2010:257058.
9. Hofmann F., García-Echeverría C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov. Today 2005, 10(15):1041-1047.
10. Girnita A., et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004, 64(1):236-242.
11. Vasilcanu D., et al. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 2004, 23(47):7854-7862.
12. Jin M., Buck E., Mulvihill M.J. Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives. Oncol. Rev 2013, 7(1):e3.
13. Werner H. Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene 2012, 31(22):2703-2714.
14. Girnita L., Girnita A., Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(14):8247-8252.
15. Lutz A.M., et al. Early diagnosis of ovarian carcinoma: is a solution in sight?. Radiology 2011, 259(2):329-345.
16. Gubbels J.A., et al. The detection, treatment, and biology of epithelial ovarian cancer. J. Ovarian Res 2010, 3:8.
17. Ozols R.F. Challenges for chemotherapy in ovarian cancer. Ann. Oncol 2006, 17(Suppl. 5):v181-v187.
18. Dallas N.A., et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-1 receptor inhibition. Cancer Res 2009, 69(5):1951-1957.
19. Eckstein N., et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009, 69(7):2996-3003.
20. Huang G.S., et al. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin. Cancer Res 2010, 16(11):2999-3010.
21. Gaikwad S.M., et al. Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models. PLoS ONE 2013, 8(2):e55971.
22. Goel H.L., et al. VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov 2012, 2(10):906-921.
23. Idelman G., et al. WT1-p53 interactions in insulin-like growth factor-I receptor gene regulation. J. Biol. Chem 2003, 278(5):3474-3482.
24. Parrella P., et al. Molecular analysis of peritoneal fluid in ovarian cancer patients. Mod. Pathol 2003, 16(7):636-640.
25. Veatch A.L., Carson L.F., Ramakrishnan S. Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int. J. Cancer 1994, 58(3):393-399.
26. Provencher D.M., et al. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Gynecol. Oncol 1993, 50(1):78-83.
27. Ho C.M., et al. Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma. J. Biomed. Sci 2012, 19:23.
28. Pliarchopoulou K., Pectasides D. Epithelial ovarian cancer: focus on targeted therapy. Crit. Rev. Oncol. Hematol 2011, 79(1):17-23.
29. Ozols R.F., et al. Focus on epithelial ovarian cancer. Cancer Cell 2004, 5(1):19-24.
30. Agarwal R., Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3(7):502-516.
31. Sprowl J.A., et al. Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells. Breast Cancer Res 2012, 14(1):R2.
32. Marchion D.C., et al. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin. Cancer Res 2011, 17(19):6356-6366.
33. Armstrong S.R., et al. Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel. J. Ovarian Res 2012, 5(1):40.
34. Auersperg N., et al. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev 2001, 22(2):255-288.
35. Kuroda H., et al. Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of insulin-like growth factor-1 by hCG. Int. J. Cancer 1998, 76(4):571-578.
36. Poretsky L., et al. The insulin-related ovarian regulatory system in health and disease. Endocr. Rev 1999, 20(4):535-582.
37. Chandarlapaty S., et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19(1):58-71.
38. Kai K., et al. Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009, 278(1):49-55.
39. Lu X., et al. Picropodophyllin inhibits epithelial ovarian cancer cells in vitro and in vivo. Biochem. Biophys. Res. Commun 2013, 435(3):385-390.